

Interactions with COVID-19 Antiviral Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 1 of 11

Please check www.covid19-druginteractions.org for updates.

Please note if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers. Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

	ESV	FAVI	MOL	NIC	NM/r 5 day	NM/r ≥10 day	NTZ	RDV
ADHD Agents								
Amphetamine mixed salts	◆	◆	◆	◆	■	■	◆	◆
Atomoxetine	■	◆	◆	◆	■	■	◆	▲
Dexamfetamine	◆	◆	◆	◆	■	■	◆	◆
Dexmethylphenidate	◆	◆	◆	◆	◆	◆	◆	◆
Guanfacine	■	◆	◆	◆	■	■	◆	■
Lisdexamfetamine	◆	◆	◆	◆	■	■	◆	◆
Methylphenidate	◆	◆	◆	◆	◆	◆	◆	◆
Anaesthetics & Muscle Relaxants								
Alcuronium	◆	▲	◆	◆	◆	◆	◆	◆
Bupivacaine	■	◆	◆	◆	■	■	◆	◆
Cisatracurium	◆	◆	◆	◆	◆	◆	◆	◆
Cyclobenzaprine	▲	◆	◆	◆	▲	▲	◆	◆
Desflurane	◆	◆	◆	◆	◆	◆	◆	◆
Dexmedetomidine	◆	◆	◆	◆	◆	■	◆	▲
Enflurane	◆	◆	◆	◆	◆	◆	◆	◆
Ephedrine	◆	◆	◆	◆	◆	◆	◆	◆
Etidocaine	■	◆	◆	◆	■	■	◆	◆
Halothane	◆	◆	◆	◆	◆	◆	◆	◆
Isoflurane	◆	◆	◆	◆	◆	◆	◆	◆
Ketamine	■	◆	◆	◆	■	■	◆	◆
Methocarbamol	◆	◆	◆	◆	◆	◆	◆	◆
Nitrous oxide	◆	◆	◆	◆	◆	◆	◆	◆
Propofol	◆	◆	◆	◆	◆	▲	◆	■
Rocuronium	■	◆	◆	◆	■	■	◆	◆
Ropivacaine	◆	◆	◆	◆	◆	■	◆	◆
Sevoflurane	◆	◆	◆	◆	◆	◆	◆	■
Sufentanil	■	◆	◆	◆	■	■	◆	◆
Suxamethonium (succinylcholine)	◆	◆	◆	◆	◆	◆	◆	◆
Tetracaine	◆	◆	◆	◆	◆	◆	◆	◆
Thiopental	◆	◆	◆	◆	◆	◆	◆	◆
Tizanidine	◆	◆	◆	◆	◆	■	◆	▲
Vecuronium	◆	◆	◆	◆	◆	◆	◆	◆
Analgesics								
Alfentanil	●	◆	◆	◆	■	■	◆	◆
Aspirin	◆	◆	◆	◆	◆	◆	◆	◆
Buprenorphine	▲	◆	◆	◆	▲	▲	◆	▲
Butalbital	◆	◆	◆	◆	◆	◆	◆	◆
Celecoxib	◆	◆	◆	◆	◆	◆	◆	◆
Codeine	◆	◆	◆	◆	▲	▲	◆	◆
Dexketoprofen	◆	◆	◆	◆	◆	◆	◆	◆
Dextropropoxyphene	●	◆	◆	◆	●	●	◆	◆
Diamorphine (diacetylmorphine)	◆	◆	◆	◆	■	■	◆	◆
Diclofenac	◆	◆	◆	◆	◆	◆	◆	◆
Dihydrocodeine	■	◆	◆	◆	■	■	◆	◆
Etoricoxib	◆	◆	◆	◆	◆	◆	◆	◆
Fentanyl	■	◆	◆	◆	■	■	◆	◆
Hydrocodone	■	◆	◆	◆	■	■	◆	▲
Hydromorphone	◆	◆	◆	◆	▲	■	◆	◆
Ibuprofen	◆	◆	◆	◆	◆	◆	◆	◆
Indometacin (Indomethacin)	◆	◆	◆	◆	◆	◆	◆	◆
Ketoprofen	◆	◆	◆	◆	◆	◆	◆	◆
Ketorolac	◆	◆	◆	◆	◆	◆	◆	◆
Mefenamic acid	◆	◆	◆	◆	◆	◆	◆	◆
Meloxicam	◆	◆	◆	◆	◆	◆	◆	◆
Metamizole	●	◆	◆	◆	■	■	◆	◆
Methadone	■	◆	◆	◆	▲	▲	◆	■
Morphine	◆	◆	◆	◆	■	■	◆	◆

	ESV	FAVI	MOL	NIC	NM/r 5 day	NM/r ≥10 day	NTZ	RDV
Analgesics (continued)								
Nabumetone	◆	◆	◆	◆	◆	◆	▲	◆
Naproxen	◆	◆	◆	◆	◆	◆	◆	◆
Nefopam	▲	◆	◆	◆	▲	▲	◆	◆
Nimesulide	◆	◆	◆	◆	◆	◆	◆	◆
Oxycodone	■	◆	◆	◆	■	■	◆	◆
Paracetamol (Acetaminophen)	◆	■	◆	◆	◆	◆	◆	◆
Pethidine (Meperidine)	■	◆	◆	◆	■	■	◆	◆
Piroxicam	◆	◆	◆	◆	◆	◆	◆	◆
Remifentanyl	◆	◆	◆	◆	◆	◆	◆	◆
Tapentadol	◆	◆	◆	◆	◆	◆	◆	◆
Tramadol	■	◆	◆	◆	■	■	◆	▲
Antiarrhythmics								
Amiodarone	●	◆	◆	◆	●	●	◆	■
Bepidil	●	◆	◆	◆	●	●	◆	■
Digoxin	■	◆	◆	◆	■	■	◆	◆
Disopyramide	●	◆	◆	◆	●	●	◆	■
Dofetilide	●	◆	◆	◆	●	●	◆	■
Dronedarone	●	◆	◆	◆	●	●	◆	■
Flecainide	◆	◆	◆	◆	●	●	◆	■
Lidocaine (Lignocaine)	◆	◆	◆	◆	■	■	◆	◆
Mexiletine	◆	◆	◆	◆	■	■	◆	◆
Propafenone	●	◆	◆	◆	●	●	◆	◆
Quinidine	●	◆	◆	◆	●	●	◆	■
Antibacterials								
Amikacin	◆	◆	◆	◆	◆	◆	◆	◆
Amoxicillin	◆	◆	◆	◆	◆	◆	◆	◆
Ampicillin	◆	◆	◆	◆	◆	◆	◆	◆
Azithromycin	◆	◆	◆	◆	◆	◆	◆	■
Bedaquiline	■	◆	◆	◆	■	■	◆	▲
Capreomycin	◆	◆	◆	◆	◆	◆	◆	◆
Cefalexin	◆	◆	◆	◆	◆	◆	◆	◆
Cefazolin	◆	◆	◆	◆	◆	◆	◆	◆
Cefepime	◆	◆	◆	◆	◆	◆	◆	◆
Cefixime	◆	◆	◆	◆	◆	◆	◆	◆
Cefotaxime	◆	◆	◆	◆	◆	◆	◆	◆
Ceftazidime	◆	◆	◆	◆	◆	◆	◆	◆
Ceftriaxone	◆	◆	◆	◆	◆	◆	◆	◆
Cefuroxime	◆	◆	◆	◆	◆	◆	◆	◆
Chloramphenicol	◆	◆	◆	◆	◆	◆	◆	◆
Ciprofloxacin	◆	◆	◆	◆	◆	◆	◆	■
Clarithromycin	■	◆	◆	◆	■	■	◆	■
Clavulanic acid	◆	◆	◆	◆	◆	◆	◆	◆
Clindamycin	▲	◆	◆	◆	▲	■	◆	◆
Clofazimine	◆	◆	◆	◆	◆	◆	◆	◆
Cloxacillin	◆	◆	◆	◆	◆	◆	◆	◆
Cycloserine	◆	◆	◆	◆	◆	◆	◆	◆
Dapsone	◆	◆	◆	◆	◆	◆	◆	◆
Delamanid	■	◆	◆	◆	■	■	◆	▲
Doxycycline	◆	◆	◆	◆	◆	◆	◆	◆
Ertapenem	◆	◆	◆	◆	◆	◆	◆	◆
Erythromycin	■	◆	◆	◆	■	■	◆	■
Ethambutol	◆	◆	◆	◆	◆	◆	◆	◆
Ethionamide	◆	◆	◆	◆	◆	◆	◆	◆
Flucloxacillin	■	◆	◆	◆	◆	◆	◆	◆
Fosfomycin	◆	◆	◆	◆	◆	◆	◆	◆
Furazolidone	◆	◆	◆	◆	◆	◆	◆	◆
Fusidic acid (oral or IV)	●	◆	◆	◆	●	●	◆	◆
Fusidic acid (topical)	◆	◆	◆	◆	◆	◆	◆	◆
Gentamicin	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations


ESV	Ensitrelvir	NIC	Niclosamide
FAVI	Favipiravir	NM/r	Nirmatrelvir/ritonavir
MOL	Molnupiravir	NTZ	Nitazoxanide
		RDV	Remdesivir

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with COVID-19 Antiviral Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 2 of 11

Please check www.covid19-druginteractions.org for updates.

Please note if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers. Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

	ESV	FAVI	MOL	NIC	NMVR/r 5 day	NMVR/r ≥10 day	NTZ	RDV
Antibacterials (continued)								
Imipenem/Cilastatin	◆	◆	◆	◆	◆	◆	◆	◆
Isoniazid	◆	◆	◆	◆	◆	◆	◆	◆
Kanamycin	◆	◆	◆	◆	◆	◆	◆	◆
Levofloxacin	◆	◆	◆	◆	◆	◆	◆	◆
Linezolid	◆	◆	◆	◆	◆	◆	◆	◆
Lymecycline	◆	◆	◆	◆	◆	◆	◆	◆
Meropenem	◆	◆	◆	◆	◆	◆	◆	◆
Metronidazole	◆	◆	◆	◆	◆	◆	◆	◆
Minocycline	◆	◆	◆	◆	◆	◆	◆	◆
Moxifloxacin	◆	◆	◆	◆	◆	◆	◆	◆
Nitrofurantoin	◆	◆	◆	◆	◆	◆	◆	◆
Ofloxacin	◆	◆	◆	◆	◆	◆	◆	◆
Para-aminosalicylic acid	◆	◆	◆	◆	◆	◆	◆	◆
Penicillins	◆	◆	◆	◆	◆	◆	◆	◆
Piperacillin	◆	◆	◆	◆	◆	◆	◆	◆
Pyrazinamide	◆	◆	◆	◆	◆	◆	◆	◆
Rifabutin	◆	◆	◆	◆	◆	◆	◆	◆
Rifampicin (Rifampin)	◆	◆	◆	◆	◆	◆	◆	◆
Rifapentine	◆	◆	◆	◆	◆	◆	◆	◆
Rifaximin	◆	◆	◆	◆	◆	◆	◆	◆
Spectinomycin	◆	◆	◆	◆	◆	◆	◆	◆
Streptomycin	◆	◆	◆	◆	◆	◆	◆	◆
Sulfadiazine	◆	◆	◆	◆	◆	◆	◆	◆
Tazobactam	◆	◆	◆	◆	◆	◆	◆	◆
Teicoplanin	◆	◆	◆	◆	◆	◆	◆	◆
Telavancin	◆	◆	◆	◆	◆	◆	◆	◆
Telithromycin	◆	◆	◆	◆	◆	◆	◆	◆
Tetracyclines	◆	◆	◆	◆	◆	◆	◆	◆
Tinidazole	◆	◆	◆	◆	◆	◆	◆	◆
Tobramycin	◆	◆	◆	◆	◆	◆	◆	◆
Trimethoprim/Sulfamethoxazole	◆	◆	◆	◆	◆	◆	◆	◆
Vancomycin	◆	◆	◆	◆	◆	◆	◆	◆
Anti-coagulant, Anti-platelet and Fibrinolytic								
Acenocoumarol	◆	◆	◆	◆	◆	◆	◆	◆
Apixaban	◆	◆	◆	◆	◆	◆	◆	◆
Argatroban	◆	◆	◆	◆	◆	◆	◆	◆
Aspirin (anti-platelet)	◆	◆	◆	◆	◆	◆	◆	◆
Betrixaban	◆	◆	◆	◆	◆	◆	◆	◆
Cilostazol	◆	◆	◆	◆	◆	◆	◆	◆
Clopidogrel	◆	◆	◆	◆	◆	◆	◆	◆
Clopidogrel (recently stented patients)	◆	◆	◆	◆	◆	◆	◆	◆
Dabigatran	◆	◆	◆	◆	◆	◆	◆	◆
Dalteparin	◆	◆	◆	◆	◆	◆	◆	◆
Dipyridamole	◆	◆	◆	◆	◆	◆	◆	◆
Edoxaban	◆	◆	◆	◆	◆	◆	◆	◆
Enoxaparin	◆	◆	◆	◆	◆	◆	◆	◆
Fondaparinux	◆	◆	◆	◆	◆	◆	◆	◆
Heparin	◆	◆	◆	◆	◆	◆	◆	◆
Phenprocoumon	◆	◆	◆	◆	◆	◆	◆	◆
Prasugrel	◆	◆	◆	◆	◆	◆	◆	◆
Rivaroxaban	◆	◆	◆	◆	◆	◆	◆	◆
Streptokinase	◆	◆	◆	◆	◆	◆	◆	◆
Ticagrelor	◆	◆	◆	◆	◆	◆	◆	◆
Ticlopidine	◆	◆	◆	◆	◆	◆	◆	◆
Tinzaparin	◆	◆	◆	◆	◆	◆	◆	◆
Vorapaxar	◆	◆	◆	◆	◆	◆	◆	◆
Warfarin	◆	◆	◆	◆	◆	◆	◆	◆

	ESV	FAVI	MOL	NIC	NMVR/r 5 day	NMVR/r ≥10 day	NTZ	RDV
Anticonvulsants								
Brivaracetam	◆	◆	◆	◆	◆	◆	◆	◆
Carbamazepine	◆	◆	◆	◆	◆	◆	◆	◆
Cenobamate	◆	◆	◆	◆	◆	◆	◆	◆
Clonazepam	◆	◆	◆	◆	◆	◆	◆	◆
Eslicarbazepine	◆	◆	◆	◆	◆	◆	◆	◆
Ethosuximide	◆	◆	◆	◆	◆	◆	◆	◆
Fosphenytoin	◆	◆	◆	◆	◆	◆	◆	◆
Gabapentin	◆	◆	◆	◆	◆	◆	◆	◆
Lacosamide	◆	◆	◆	◆	◆	◆	◆	◆
Lamotrigine	◆	◆	◆	◆	◆	◆	◆	◆
Levetiracetam	◆	◆	◆	◆	◆	◆	◆	◆
Oxcarbazepine	◆	◆	◆	◆	◆	◆	◆	◆
Perampanel	◆	◆	◆	◆	◆	◆	◆	◆
Phenobarbital (Phenobarbitone)	◆	◆	◆	◆	◆	◆	◆	◆
Phenytoin	◆	◆	◆	◆	◆	◆	◆	◆
Pregabalin	◆	◆	◆	◆	◆	◆	◆	◆
Primidone	◆	◆	◆	◆	◆	◆	◆	◆
Retigabine	◆	◆	◆	◆	◆	◆	◆	◆
Rufinamide	◆	◆	◆	◆	◆	◆	◆	◆
Sodium valproate	◆	◆	◆	◆	◆	◆	◆	◆
Sultiame	◆	◆	◆	◆	◆	◆	◆	◆
Tiagabine	◆	◆	◆	◆	◆	◆	◆	◆
Topiramate	◆	◆	◆	◆	◆	◆	◆	◆
Valproate semisodium (Divalproex)	◆	◆	◆	◆	◆	◆	◆	◆
Valproic acid	◆	◆	◆	◆	◆	◆	◆	◆
Vigabatrin	◆	◆	◆	◆	◆	◆	◆	◆
Zonisamide	◆	◆	◆	◆	◆	◆	◆	◆
Antidepressants								
Agomelatine	◆	◆	◆	◆	◆	◆	◆	◆
Amitriptyline	◆	◆	◆	◆	◆	◆	◆	◆
Bupropion	◆	◆	◆	◆	◆	◆	◆	◆
Citalopram	◆	◆	◆	◆	◆	◆	◆	◆
Clomipramine	◆	◆	◆	◆	◆	◆	◆	◆
Desipramine	◆	◆	◆	◆	◆	◆	◆	◆
Desvenlafaxine	◆	◆	◆	◆	◆	◆	◆	◆
Doxepin	◆	◆	◆	◆	◆	◆	◆	◆
Duloxetine	◆	◆	◆	◆	◆	◆	◆	◆
Escitalopram	◆	◆	◆	◆	◆	◆	◆	◆
Fluoxetine	◆	◆	◆	◆	◆	◆	◆	◆
Imipramine	◆	◆	◆	◆	◆	◆	◆	◆
Lithium	◆	◆	◆	◆	◆	◆	◆	◆
Maprotiline	◆	◆	◆	◆	◆	◆	◆	◆
Mianserin	◆	◆	◆	◆	◆	◆	◆	◆
Milnacipran	◆	◆	◆	◆	◆	◆	◆	◆
Mirtazapine	◆	◆	◆	◆	◆	◆	◆	◆
Moclobemide	◆	◆	◆	◆	◆	◆	◆	◆
Nefazodone	◆	◆	◆	◆	◆	◆	◆	◆
Nortriptyline	◆	◆	◆	◆	◆	◆	◆	◆
Opipramol	◆	◆	◆	◆	◆	◆	◆	◆
Paroxetine	◆	◆	◆	◆	◆	◆	◆	◆
Phenelzine	◆	◆	◆	◆	◆	◆	◆	◆
Reboxetine	◆	◆	◆	◆	◆	◆	◆	◆
Sertraline	◆	◆	◆	◆	◆	◆	◆	◆
Tranlycypromine	◆	◆	◆	◆	◆	◆	◆	◆
Trazodone	◆	◆	◆	◆	◆	◆	◆	◆
Trimipramine	◆	◆	◆	◆	◆	◆	◆	◆
Venlafaxine	◆	◆	◆	◆	◆	◆	◆	◆
Vilazodone	◆	◆	◆	◆	◆	◆	◆	◆
Vortioxetine	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ESV	Ensitrelvir	NIC	Niclosamide
FAVI	Favipiravir	NMVR/r	Nirmatrelvir/ritonavir
MOL	Molnupiravir	NTZ	Nitazoxanide
		RDV	Remdesivir

Key to symbols

●	These drugs should not be coadministered
◆	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?

Click or scan to check for updates



Interactions with COVID-19 Antiviral Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 3 of 11

Please check www.covid19-druginteractions.org for updates.

Please note if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

	ESV	FAVI	MOL	NIC	NM/r 5 day	NM/r ≥10 day	NTZ	RDV
Anti-diabetics								
Acarbose	◆	◆	◆	◆	◆	◆	◆	◆
Alogliptin	◆	◆	◆	◆	◆	◆	◆	◆
Canagliflozin	◆	◆	◆	◆	◆	◆	◆	◆
Dapagliflozin	◆	◆	◆	◆	◆	◆	◆	◆
Dulaglutide	◆	◆	◆	◆	◆	◆	◆	◆
Empagliflozin	◆	◆	◆	◆	◆	◆	◆	◆
Exenatide	◆	◆	◆	◆	◆	◆	◆	◆
Glibenclamide (Glyburide)	■	◆	◆	◆	■	■	◆	◆
Gliclazide	◆	◆	◆	◆	◆	◆	◆	◆
Glimepiride	◆	◆	◆	◆	◆	◆	◆	◆
Glipizide	◆	◆	◆	◆	◆	◆	◆	◆
Insulin	◆	◆	◆	◆	◆	◆	◆	◆
Linagliptin	◆	◆	◆	◆	◆	◆	◆	◆
Liraglutide	◆	◆	◆	◆	◆	◆	◆	◆
Metformin	◆	◆	◆	◆	◆	◆	◆	◆
Nateglinide	◆	◆	◆	◆	◆	◆	◆	◆
Pioglitazone	◆	■	◆	◆	◆	◆	◆	◆
Repaglinide	■	■	◆	◆	■	■	◆	◆
Rosiglitazone	◆	■	◆	◆	◆	◆	◆	◆
Saxagliptin	■	◆	◆	◆	■	■	◆	◆
Semaglutide	◆	◆	◆	◆	◆	◆	◆	◆
Sitagliptin	◆	◆	◆	◆	◆	◆	◆	◆
Tirzepatide	◆	◆	◆	◆	◆	◆	◆	◆
Tolbutamide	◆	◆	◆	◆	◆	◆	◆	◆
Vildagliptin	◆	◆	◆	◆	◆	◆	◆	◆
Antifungals								
Amphotericin B	◆	◆	◆	◆	◆	◆	◆	◆
Anidulafungin	◆	◆	◆	◆	◆	◆	◆	◆
Caspofungin	◆	◆	◆	◆	◆	◆	◆	◆
Clotrimazole (pessary, troche)	◆	◆	◆	◆	◆	◆	◆	◆
Clotrimazole (topical)	◆	◆	◆	◆	◆	◆	◆	◆
Fluconazole	◆	◆	◆	◆	◆	◆	◆	■
Flucytosine	◆	◆	◆	◆	◆	◆	◆	◆
Griseofulvin	◆	◆	◆	◆	◆	◆	◆	◆
Isavuconazole	▲	◆	◆	◆	▲	■	◆	◆
Itraconazole	■	◆	◆	◆	■	■	◆	◆
Ketoconazole	■	◆	◆	◆	■	■	◆	◆
Micafungin	◆	◆	◆	◆	◆	◆	◆	◆
Miconazole	◆	◆	◆	◆	◆	◆	◆	◆
Nystatin	◆	◆	◆	◆	◆	◆	◆	◆
Posaconazole	■	◆	◆	◆	■	■	◆	◆
Rezafungin	◆	◆	◆	◆	◆	◆	◆	◆
Terbinafine	◆	◆	◆	◆	◆	◆	◆	◆
Voriconazole	■	◆	◆	◆	■	■	◆	◆
Antihæmorrhagics								
Avatrombopag	■	◆	◆	◆	■	■	◆	◆
Eltrombopag	◆	◆	◆	◆	▲	■	◆	◆
Emicizumab	◆	◆	◆	◆	◆	◆	◆	◆
Fostamatinib	■	◆	◆	◆	■	■	◆	◆
Tranexamic acid	◆	◆	◆	◆	◆	◆	◆	◆

	ESV	FAVI	MOL	NIC	NM/r 5 day	NM/r ≥10 day	NTZ	RDV
Antihistamines								
Azelastine	◆	◆	◆	◆	◆	◆	◆	◆
Bilastine	▲	◆	◆	◆	■	■	◆	◆
Cetirizine	◆	◆	◆	◆	◆	◆	◆	◆
Chlorphenamine	◆	◆	◆	◆	◆	▲	◆	◆
Desloratadine	◆	◆	◆	◆	◆	◆	◆	◆
Diphenhydramine	◆	◆	◆	◆	◆	▲	◆	◆
Doxylamine	◆	◆	◆	◆	◆	■	◆	◆
Fexofenadine	◆	◆	◆	◆	◆	▲	◆	◆
Levocetirizine	◆	◆	◆	◆	◆	◆	◆	◆
Loratadine	▲	◆	◆	◆	◆	▲	◆	◆
Meclizine	◆	◆	◆	◆	◆	▲	◆	◆
Promethazine	◆	◆	◆	◆	◆	◆	◆	▲
Antimalarials								
Amodiaquine	◆	■	◆	◆	■	■	◆	◆
Artemether	■	◆	◆	◆	▲	■	◆	◆
Artesunate	◆	◆	◆	◆	▲	■	◆	◆
Atovaquone	◆	◆	◆	◆	◆	■	◆	◆
Chloroquine	■	◆	◆	◆	■	■	◆	●
Halofantrine	●	◆	◆	◆	●	●	◆	■
Hydroxychloroquine	▲	◆	◆	◆	▲	▲	◆	●
Lumefantrine	◆	◆	◆	◆	■	■	◆	▲
Mefloquine	■	◆	◆	◆	■	■	◆	◆
Piperazine	■	◆	◆	◆	■	■	◆	▲
Primaquine	◆	◆	◆	◆	◆	◆	◆	▲
Proguanil	◆	◆	◆	◆	◆	■	◆	◆
Pyrimethamine	◆	◆	◆	◆	◆	◆	◆	◆
Quinine	■	◆	◆	◆	■	■	◆	◆
Sulfadoxine	◆	◆	◆	◆	◆	◆	◆	◆
Antimigraine Agents								
Almotriptan	■	◆	◆	◆	■	■	◆	◆
Atogepant	■	◆	◆	◆	■	■	◆	◆
Dihydroergotamine	●	◆	◆	◆	●	●	◆	◆
Eletriptan	●	◆	◆	◆	●	●	◆	◆
Eptinezumab	◆	◆	◆	◆	◆	◆	◆	◆
Erenumab	◆	◆	◆	◆	◆	◆	◆	◆
Ergotamine	●	◆	◆	◆	●	●	◆	◆
Fremanuzemab	◆	◆	◆	◆	◆	◆	◆	◆
Frovatriptan	◆	◆	◆	◆	◆	■	◆	◆
Galcanezumab	◆	◆	◆	◆	◆	◆	◆	◆
Naratriptan	◆	◆	◆	◆	◆	◆	◆	◆
Pizotifen	◆	◆	◆	◆	◆	■	◆	◆
Rimegepant	●	◆	◆	◆	●	●	◆	◆
Rizatriptan	◆	◆	◆	◆	◆	◆	◆	◆
Sumatriptan	◆	◆	◆	◆	◆	◆	◆	◆
Ubrogepant	●	◆	◆	◆	●	●	◆	◆
Zolmitriptan	◆	◆	◆	◆	■	■	◆	◆

Key to abbreviations

ESV	Ensitrivir	NIC	Niclosamide
FAVI	Favipiravir	NM/r	Nirmatrelvir/ritonavir
MOL	Molnupiravir	NTZ	Nitazoxanide
		RDV	Remdesivir

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?

Click or scan to check for updates



Interactions with COVID-19 Antiviral Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 4 of 11

Please check www.covid19-druginteractions.org for updates.

Please note if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

	ESV	FAVI	MOL	NIC	NM/r 5 day	NM/r ≥10 day	NTZ	RDV
Antipsychotics/Neuroleptics								
Amisulpride	◆	◆	◆	◆	◆	◆	◆	◆
Aripiprazole	■	◆	◆	◆	■	■	◆	▲
Asenapine	◆	◆	◆	◆	◆	■	◆	◆
Brexpiprazole	■	◆	◆	◆	■	■	◆	◆
Cariprazine	●	◆	◆	◆	●	●	◆	◆
Chlorpromazine	◆	▲	◆	◆	▲	▲	◆	◆
Clozapine	●	◆	◆	◆	■	■	◆	▲
Flupentixol (Flupentixol)	■	◆	◆	◆	■	■	◆	▲
Fluphenazine	◆	◆	◆	◆	◆	◆	◆	◆
Haloperidol	■	◆	◆	◆	■	■	◆	■
Iloperidone	■	◆	◆	◆	■	■	◆	▲
Levomopromazine	◆	◆	◆	◆	▲	▲	◆	■
Lumateperone	●	◆	◆	◆	■	■	◆	◆
Lurasidone	●	◆	◆	◆	●	●	◆	▲
Olanzapine	◆	◆	◆	◆	◆	■	◆	◆
Paliperidone	◆	◆	◆	◆	▲	▲	◆	▲
Perazine	■	◆	◆	◆	■	■	◆	▲
Periciazine	◆	◆	◆	◆	◆	◆	◆	▲
Perphenazine	◆	▲	◆	◆	▲	▲	◆	▲
Pimavanserin	■	◆	◆	◆	■	■	◆	▲
Pimozide	●	◆	◆	◆	●	●	◆	◆
Pipotiazine	◆	◆	◆	◆	◆	◆	◆	◆
Quetiapine	●	▲	◆	◆	●	●	◆	◆
Risperidone	■	◆	◆	◆	■	■	◆	◆
Sulpiride	◆	◆	◆	◆	◆	◆	◆	◆
Thioridazine	■	▲	◆	◆	■	■	◆	■
Tiapride	◆	◆	◆	◆	◆	◆	◆	▲
Ziprasidone	▲	◆	◆	◆	■	■	◆	◆
Zotepine	■	◆	◆	◆	■	■	◆	▲
Zuclopenthixol	■	◆	◆	◆	■	■	◆	▲
Antivirals								
Aciclovir	◆	◆	◆	◆	◆	◆	◆	◆
Adefovir	◆	■	◆	◆	◆	◆	◆	◆
Baloxavir	◆	◆	◆	◆	◆	◆	◆	◆
Brincidofovir	◆	◆	◆	◆	■	■	◆	◆
Bulevirtide	◆	◆	◆	◆	●	●	◆	◆
Cidofovir	◆	■	◆	◆	◆	◆	◆	◆
Entecavir	◆	◆	◆	◆	◆	◆	◆	◆
Famciclovir	◆	■	◆	◆	◆	◆	◆	◆
Foscarnet	◆	◆	◆	◆	◆	◆	◆	◆
Ganciclovir	◆	■	◆	◆	◆	◆	◆	◆
Letermovir	◆	◆	◆	◆	◆	●	◆	◆
Maribavir	◆	◆	◆	◆	◆	◆	◆	◆
Oseltamivir	◆	◆	◆	◆	◆	◆	◆	◆
Ribavirin	◆	◆	◆	◆	◆	◆	◆	◆
Rimantadine	◆	◆	◆	◆	◆	◆	◆	◆
Tecovirimat	◆	◆	◆	◆	◆	◆	◆	◆
Telbivudine	◆	◆	◆	◆	◆	◆	◆	◆
Tenofovir alafenamide (HBV)	◆	◆	◆	◆	◆	◆	◆	◆
Valaciclovir (Valacyclovir)	◆	◆	◆	◆	◆	◆	◆	◆
Valganciclovir	◆	◆	◆	◆	◆	◆	◆	◆
Zanamivir	◆	◆	◆	◆	◆	◆	◆	◆

	ESV	FAVI	MOL	NIC	NM/r 5 day	NM/r ≥10 day	NTZ	RDV
Anxiolytics/Hypnotics/Sedatives								
Alprazolam	■	◆	◆	◆	■	■	◆	◆
Bromazepam	▲	◆	◆	◆	◆	▲	◆	◆
Bupirone	■	◆	◆	◆	■	■	◆	◆
Chlordiazepoxide	■	◆	◆	◆	■	■	◆	◆
Clobazam	■	◆	◆	◆	■	■	◆	◆
Clorazepate	●	◆	◆	◆	●	●	◆	◆
Daridorexant	●	◆	◆	◆	●	●	◆	◆
Diazepam	●	◆	◆	◆	●	●	◆	◆
Estazolam	●	◆	◆	◆	●	●	◆	◆
Eszopiclone	■	◆	◆	◆	■	■	◆	◆
Flunitrazepam	■	◆	◆	◆	■	■	◆	◆
Flurazepam	●	◆	◆	◆	●	●	◆	◆
Hydroxyzine	■	◆	◆	◆	■	■	◆	◆
Lorazepam	◆	◆	◆	◆	◆	◆	◆	◆
Lormetazepam	◆	◆	◆	◆	◆	◆	◆	◆
Midazolam (buccal)	■	◆	◆	◆	■	■	◆	◆
Midazolam (oral)	●	◆	◆	◆	●	●	◆	◆
Midazolam (parenteral)	■	◆	◆	◆	■	■	◆	◆
Oxazepam	◆	◆	◆	◆	◆	◆	◆	◆
Suvorexant	●	◆	◆	◆	●	●	◆	◆
Temazepam	◆	◆	◆	◆	◆	◆	◆	◆
Triazolam	●	◆	◆	◆	●	●	◆	◆
Zaleplon	◆	■	◆	◆	◆	◆	◆	◆
Zolpidem	■	◆	◆	◆	■	■	◆	◆
Zopiclone	■	◆	◆	◆	■	■	◆	◆
Benign Prostatic Hyperplasia Therapies								
Alfuzosin	●	◆	◆	◆	●	●	◆	▲
Dutasteride	■	◆	◆	◆	■	■	◆	◆
Finasteride (5 mg)	◆	◆	◆	◆	◆	◆	◆	◆
Silodosin	●	◆	◆	◆	●	●	◆	◆
Tadalafil (BPH)	■	◆	◆	◆	■	■	◆	◆
Tamsulosin	■	◆	◆	◆	■	■	◆	◆
Beta Blockers								
Atenolol	◆	◆	◆	◆	◆	◆	◆	▲
Bisoprolol	◆	◆	◆	◆	◆	◆	◆	▲
Carvedilol	◆	◆	◆	◆	◆	◆	◆	▲
Metoprolol	◆	◆	◆	◆	◆	◆	◆	▲
Nebivolol	◆	◆	◆	◆	◆	◆	◆	▲
Oxprenolol	◆	◆	◆	◆	◆	■	◆	▲
Pindolol	◆	◆	◆	◆	◆	◆	◆	▲
Propranolol	◆	◆	◆	◆	◆	◆	◆	▲
Sotalol	◆	◆	◆	◆	◆	◆	◆	■
Timolol	◆	◆	◆	◆	◆	◆	◆	▲
Bisphosphonates								
Alendronic acid (Alendronate)	◆	◆	◆	◆	◆	◆	◆	◆
Ibandronic acid (Ibandronate)	◆	◆	◆	◆	◆	◆	◆	◆
Risedronic acid (Risedronate)	◆	◆	◆	◆	◆	◆	◆	◆
Zoledronic acid (Zoledronate)	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ESV	Ensitrivir	NIC	Niclosamide
FAVI	Favipiravir	NM/r	Nirmatrelvir/ritonavir
MOL	Molnupiravir	NTZ	Nitazoxanide
		RDV	Remdesivir

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?

Click or scan to check for updates



Interactions with COVID-19 Antiviral Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 5 of 11

Please check www.covid19-druginteractions.org for updates.

Please note if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

	ESV	FAVI	MOL	NIC	NMVR/r 5 day	NMVR/r ≥10 day	NTZ	RDV
Bronchodilators								
Acclidinium bromide	◆	◆	◆	◆	◆	◆	◆	◆
Aminophylline	◆	■	◆	◆	▲	■	◆	◆
Formoterol	◆	◆	◆	◆	◆	◆	◆	▲
Glycopyrronium bromide	◆	◆	◆	◆	◆	◆	◆	◆
Indacaterol	◆	◆	◆	◆	◆	◆	◆	◆
Ipratropium bromide	◆	◆	◆	◆	◆	◆	◆	◆
Montelukast	◆	◆	◆	◆	◆	◆	◆	◆
Olodaterol	◆	◆	◆	◆	◆	◆	◆	◆
Roflumilast	◆	◆	◆	◆	◆	◆	◆	◆
Salbutamol	◆	◆	◆	◆	◆	◆	◆	◆
Salmeterol	●	◆	◆	◆	●	●	◆	◆
Terbutaline	◆	◆	◆	◆	◆	◆	◆	◆
Theophylline	◆	■	◆	◆	▲	■	◆	◆
Tiotropium bromide	◆	◆	◆	◆	◆	◆	◆	◆
Umeclidinium bromide	◆	◆	◆	◆	◆	◆	◆	◆
Vilanterol	◆	◆	◆	◆	◆	◆	◆	◆
Calcium Channel Blockers								
Amlodipine	■	◆	◆	◆	■	■	◆	▲
Diltiazem	■	◆	◆	◆	■	■	◆	◆
Felodipine	■	▲	◆	◆	■	■	◆	▲
Nicardipine	■	◆	◆	◆	■	■	◆	▲
Nifedipine	■	◆	◆	◆	■	■	◆	▲
Nisoldipine	●	◆	◆	◆	●	●	◆	▲
Nitrendipine	■	◆	◆	◆	■	■	◆	▲
Verapamil	■	◆	◆	◆	■	■	◆	▲
Cancer Therapies								
Abemaciclib	■	◆	◆	◆	■	■	◆	◆
Abiraterone	◆	◆	◆	◆	◆	◆	◆	◆
Acalabrutinib	●	◆	◆	◆	●	●	◆	◆
Afatinib	■	◆	◆	◆	■	■	◆	◆
Aldesleukin	◆	◆	◆	◆	◆	◆	◆	◆
Alectinib	◆	◆	◆	◆	◆	◆	◆	◆
Alpelisib	◆	◆	◆	◆	◆	◆	◆	◆
Amivantamab	◆	◆	◆	◆	◆	◆	◆	◆
Anastrozole	▲	◆	◆	◆	▲	▲	◆	◆
Apalutamide	●	◆	◆	◆	●	●	◆	▲
Asciminib	■	◆	◆	◆	■	■	◆	▲
Atezolizumab	◆	◆	◆	◆	◆	◆	◆	◆
Avapritinib	●	◆	◆	◆	●	●	◆	▲
Avelumab	◆	◆	◆	◆	◆	◆	◆	◆
Axitinib	■	◆	◆	◆	■	■	◆	◆
Azacitidine	◆	◆	◆	◆	◆	◆	◆	◆
Bendamustine	◆	◆	◆	◆	◆	▲	◆	▲
Bevacizumab	◆	◆	◆	◆	◆	◆	◆	◆
Bexarotene	●	◆	◆	◆	●	●	◆	◆
Bicalutamide	◆	◆	◆	◆	◆	◆	◆	◆
Binimetinib	◆	◆	◆	◆	▲	■	◆	◆
Blinatumomab	◆	◆	◆	◆	◆	◆	◆	◆
Bortezomib	■	◆	◆	◆	■	■	◆	▲
Bosutinib	●	◆	◆	◆	●	●	◆	▲
Brentuximab vedotin	■	◆	◆	◆	■	■	◆	◆
Brigatinib	■	◆	◆	◆	■	■	◆	◆
Busulfan	■	◆	◆	◆	■	■	◆	◆
Cabazitaxel	■	◆	◆	◆	■	■	◆	◆
Cabozantinib	■	◆	◆	◆	■	■	◆	◆
Capecitabine	◆	◆	◆	◆	◆	◆	◆	▲
Capmatinib	▲	◆	◆	◆	▲	▲	◆	◆
Carboplatin	◆	◆	◆	◆	◆	◆	◆	◆

	ESV	FAVI	MOL	NIC	NMVR/r 5 day	NMVR/r ≥10 day	NTZ	RDV
Cancer Therapies (continued)								
Carfilzomib	◆	◆	◆	◆	◆	◆	◆	◆
Cedazuridine	◆	◆	◆	◆	◆	◆	◆	◆
Cemiplimab	◆	◆	◆	◆	◆	◆	◆	◆
Ceritinib	■	◆	◆	◆	■	■	◆	▲
Cetuximab	◆	◆	◆	◆	◆	◆	◆	◆
Chlorambucil	◆	◆	◆	◆	◆	◆	◆	◆
Cobimetinib	●	◆	◆	◆	●	●	◆	▲
Copanlisib	■	◆	◆	◆	■	■	◆	◆
Crizotinib	●	◆	◆	◆	●	●	◆	▲
Cyclophosphamide	▲	◆	◆	◆	▲	■	◆	▲
Dabrafenib	●	■	◆	◆	●	●	◆	▲
Dacarbazine	◆	■	◆	◆	◆	■	◆	◆
Dacomitinib	◆	◆	◆	◆	◆	◆	◆	◆
Dactinomycin	◆	◆	◆	◆	◆	◆	◆	◆
Daratumumab	◆	◆	◆	◆	◆	◆	◆	◆
Darolutamide	■	◆	◆	◆	■	■	◆	◆
Dasatinib	■	◆	◆	◆	■	■	◆	▲
Decitabine	◆	◆	◆	◆	◆	◆	◆	◆
Docetaxel	■	◆	◆	◆	■	■	◆	◆
Doxorubicin	◆	◆	◆	◆	◆	◆	◆	■
Durvalumab	◆	◆	◆	◆	◆	◆	◆	◆
Duvelisib	■	◆	◆	◆	■	■	◆	◆
Elotuzumab	◆	◆	◆	◆	◆	◆	◆	◆
Enasidenib	●	◆	◆	◆	●	●	◆	▲
Encorafenib	■	◆	◆	◆	■	■	◆	▲
Enfortumab vedotin	■	◆	◆	◆	■	■	◆	◆
Entrectinib	●	◆	◆	◆	●	●	◆	▲
Enzalutamide	●	■	◆	◆	●	●	◆	▲
Epcoritamab	◆	◆	◆	◆	◆	◆	◆	◆
Epirubicin	▲	◆	◆	◆	▲	■	◆	▲
Erdafitinib	■	◆	◆	◆	■	■	◆	◆
Eribulin	◆	◆	◆	◆	◆	◆	◆	◆
Erlotinib	■	◆	◆	◆	■	■	◆	◆
Etoposide	■	◆	◆	◆	■	■	◆	◆
Exemestane	◆	◆	◆	◆	◆	◆	◆	◆
Fedratinib	■	◆	◆	◆	■	■	◆	◆
Fluorouracil (5-FU)	◆	◆	◆	◆	◆	◆	◆	▲
Flutamide	■	◆	◆	◆	■	■	◆	▲
Fulvestrant	◆	◆	◆	◆	◆	◆	◆	◆
Gefitinib	■	◆	◆	◆	■	■	◆	◆
Gemcitabine	◆	◆	◆	◆	◆	◆	◆	◆
Gilteritinib	■	◆	◆	◆	■	■	◆	▲
Glasdegib	■	◆	◆	◆	■	■	◆	▲
Hydroxycarbamide (Hydroxyurea)	◆	◆	◆	◆	◆	◆	◆	◆
Ibrutinib	●	◆	◆	◆	●	●	◆	◆
Idarubicin	◆	◆	◆	◆	◆	◆	◆	◆
Idelalisib	■	◆	◆	◆	■	■	◆	◆
Imatinib	■	◆	◆	◆	■	■	◆	▲
Infigratinib	●	◆	◆	◆	●	●	◆	◆
Inotuzumab ozogamicin	◆	◆	◆	◆	◆	◆	◆	▲
Ipilimumab	◆	◆	◆	◆	◆	◆	◆	◆
Irinotecan	■	◆	◆	◆	■	■	◆	◆
Isatuximab	◆	◆	◆	◆	◆	◆	◆	◆
Isotretinoin	■	■	◆	◆	■	■	◆	◆
Ivosidenib	●	◆	◆	◆	●	●	◆	▲
Ixazomib	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ESV	Ensitrelvir	NIC	Niclosamide
FAVI	Favipiravir	NMVR/r	Nirmatrelvir/ritonavir
MOL	Molnupiravir	NTZ	Nitazoxanide
		RDV	Remdesivir

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?

Click or scan to check for updates



Interactions with COVID-19 Antiviral Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 6 of 11

Please check www.covid19-druginteractions.org for updates.

Please note if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

	ESV	FAVI	MOL	NIC	NMVR 5 day	NMVR ≥10 day	NTZ	RDV
Cancer Therapies (continued)								
Lapatinib	■	◆	◆	◆	■	■	◆	▲
Larotrectinib	■	◆	◆	◆	●	●	◆	◆
Lenalidomide	◆	◆	◆	◆	◆	◆	◆	◆
Lenvatinib	◆	◆	◆	◆	◆	◆	◆	▲
Letrozole	▲	◆	◆	◆	▲	▲	◆	◆
Lomustine	■	◆	◆	◆	■	■	◆	◆
Lorlatinib	●	◆	◆	◆	●	●	◆	◆
Mercaptopurine	◆	◆	◆	◆	◆	◆	◆	◆
Methotrexate	■	■	◆	◆	■	■	◆	◆
Midostaurin	●	◆	◆	◆	●	●	◆	▲
Mitomycin	◆	◆	◆	◆	◆	◆	◆	◆
Mitotane	●	◆	◆	◆	●	●	◆	▲
Mobocertinib	●	◆	◆	◆	●	●	◆	■
Necitumumab	◆	◆	◆	◆	◆	◆	◆	▲
Neratinib	●	◆	◆	◆	●	●	◆	◆
Nilotinib	■	◆	◆	◆	■	■	◆	▲
Niraparib	◆	◆	◆	◆	◆	◆	◆	◆
Nivolumab	◆	◆	◆	◆	◆	◆	◆	◆
Obinutuzumab	◆	◆	◆	◆	◆	◆	◆	◆
Ofatumumab	◆	◆	◆	◆	◆	◆	◆	◆
Olaparib	■	◆	◆	◆	■	■	◆	◆
Olaratumab	◆	◆	◆	◆	◆	◆	◆	◆
Osimertinib	◆	◆	◆	◆	◆	◆	◆	▲
Oxaliplatin	◆	◆	◆	◆	◆	◆	◆	■
Paclitaxel	■	■	◆	◆	■	■	◆	◆
Palbociclib	■	◆	◆	◆	■	■	◆	◆
Panitumumab	◆	◆	◆	◆	◆	◆	◆	◆
Panobinostat	■	◆	◆	◆	■	■	◆	▲
Pazopanib	■	◆	◆	◆	■	■	◆	▲
Pembrolizumab	◆	◆	◆	◆	◆	◆	◆	◆
Pemetrexed	◆	◆	◆	◆	◆	◆	◆	◆
Pemigatinib	●	◆	◆	◆	●	●	◆	◆
Pertuzumab	◆	◆	◆	◆	◆	◆	◆	◆
Pexidartinib	●	◆	◆	◆	●	●	◆	◆
Polatuzumab vedotin	■	◆	◆	◆	■	■	◆	◆
Pomalidomide	◆	◆	◆	◆	◆	◆	◆	◆
Ponatinib	■	◆	◆	◆	■	■	◆	◆
Pralsetinib	●	◆	◆	◆	●	●	◆	▲
Regorafenib	●	◆	◆	◆	●	●	◆	◆
Relugolix	●	◆	◆	◆	●	●	◆	▲
Reprotrectinib	●	◆	◆	◆	●	●	◆	◆
Ribociclib	■	◆	◆	◆	■	■	◆	▲
Ripretinib	■	◆	◆	◆	■	■	◆	◆
Rituximab	◆	◆	◆	◆	◆	◆	◆	◆
Romidepsin	■	◆	◆	◆	■	■	◆	▲
Rucaparib	▲	◆	◆	◆	■	■	◆	▲
Selinexor	■	◆	◆	◆	■	■	◆	◆
Selpercatinib	■	◆	◆	◆	■	■	◆	▲
Sonidegib	●	◆	◆	◆	●	●	◆	◆
Sorafenib	●	◆	◆	◆	●	●	◆	▲
Sotorasib	■	◆	◆	◆	▲	▲	◆	◆
Sunitinib	■	◆	◆	◆	■	■	◆	▲

	ESV	FAVI	MOL	NIC	NMVR 5 day	NMVR ≥10 day	NTZ	RDV
Cancer Therapies (continued)								
Talazoparib	◆	◆	◆	◆	■	■	◆	◆
Tamoxifen	▲	◆	◆	◆	▲	▲	◆	▲
Tegafur/ Gimeracil/ Oteracil	◆	◆	◆	◆	◆	◆	◆	◆
Temsirolimus	●	◆	◆	◆	●	●	◆	◆
Tepotinib	◆	◆	◆	◆	●	●	◆	▲
Thalidomide	◆	◆	◆	◆	◆	◆	◆	◆
Thiotepa	■	◆	◆	◆	■	■	◆	◆
Tisotumab vedotin	■	◆	◆	◆	■	■	◆	◆
Tivozanib	◆	◆	◆	◆	◆	◆	◆	◆
Topotecan	▲	◆	◆	◆	■	■	◆	◆
Toremifene	●	◆	◆	◆	●	●	◆	▲
Trametinib	◆	◆	◆	◆	◆	◆	◆	◆
Trastuzumab	◆	◆	◆	◆	◆	◆	◆	◆
Trastuzumab emtansine	■	◆	◆	◆	■	■	◆	◆
Trifluridine/Tipiracil	◆	◆	◆	◆	◆	◆	◆	◆
Umbralisib	●	◆	◆	◆	●	●	◆	▲
Vandetanib	■	◆	◆	◆	■	■	◆	■
Vemurafenib	■	◆	◆	◆	■	■	◆	▲
Venetoclax	●	◆	◆	◆	●	●	◆	◆
Vinblastine	■	■	◆	◆	■	■	◆	◆
Vincristine	■	◆	◆	◆	■	■	◆	◆
Vinorelbine	■	◆	◆	◆	■	■	◆	◆
Zanubrutinib	■	◆	◆	◆	■	■	◆	◆
Contraceptives/HRT								
Conjugated estrogens (HRT)	◆	▲	◆	◆	◆	▲	◆	◆
Desogestrel (COC)	◆	▲	◆	◆	▲	▲	◆	◆
Desogestrel (POP)	◆	▲	◆	◆	◆	◆	◆	◆
Drospirenone (COC)	◆	▲	◆	◆	▲	▲	◆	◆
Drospirenone (HRT)	◆	▲	◆	◆	◆	◆	◆	◆
Dydrogesterone (HRT)	◆	▲	◆	◆	◆	◆	◆	◆
Estradiol	◆	◆	◆	◆	◆	◆	◆	◆
Ethinylestradiol	◆	▲	◆	◆	▲	▲	◆	◆
Etonogestrel (implant)	◆	▲	◆	◆	◆	◆	◆	◆
Etonogestrel (vaginal ring)	◆	▲	◆	◆	▲	▲	◆	◆
Gestodene (COC)	◆	▲	◆	◆	▲	▲	◆	◆
Levonorgestrel (COC)	◆	▲	◆	◆	▲	▲	◆	◆
Levonorgestrel (emergency contrac.)	◆	▲	◆	◆	◆	◆	◆	◆
Levonorgestrel (HRT)	◆	▲	◆	◆	◆	◆	◆	◆
Levonorgestrel (implant)	◆	▲	◆	◆	◆	◆	◆	◆
Levonorgestrel (IUD)	◆	▲	◆	◆	◆	◆	◆	◆
Levonorgestrel (POP)	◆	▲	◆	◆	◆	◆	◆	◆
Medroxyprogesterone (depot inj.)	◆	◆	◆	◆	◆	◆	◆	◆
Medroxyprogesterone (oral)	◆	◆	◆	◆	◆	◆	◆	◆
Norelgestromin (patch)	◆	▲	◆	◆	◆	◆	◆	◆
Norethisterone (COC)	◆	▲	◆	◆	▲	▲	◆	◆
Norethisterone (HRT)	◆	▲	◆	◆	◆	◆	◆	◆
Norethisterone (IM depot)	◆	▲	◆	◆	◆	◆	◆	◆
Norethisterone (POP)	◆	▲	◆	◆	◆	◆	◆	◆
Norgestimate (COC)	◆	▲	◆	◆	▲	▲	◆	◆
Norgestrel (COC)	◆	▲	◆	◆	▲	▲	◆	◆
Norgestrel (HRT)	◆	▲	◆	◆	◆	◆	◆	◆
Progesterone (HRT)	◆	▲	◆	◆	◆	▲	◆	◆
Ulipristal	◆	▲	◆	◆	◆	◆	◆	◆

Key to abbreviations

ESV	Ensitrivir	NIC	Niclosamide
FAVI	Favipiravir	NMVR	Nirmatrelvir/ritonavir
MOL	Molnupiravir	NTZ	Nitazoxanide
		RDV	Remdesivir

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?

Click or scan to check for updates



Interactions with COVID-19 Antiviral Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 7 of 11

Please check www.covid19-druginteractions.org for updates.

Please note if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

	ESV	FAVI	MOL	NIC	NM/r 5 day	NM/r ≥10 day	NTZ	RDV
Cough and Cold Preparations								
Benzonatate	◆	◆	◆	◆	◆	◆	◆	◆
Carbocisteine	◆	◆	◆	◆	◆	◆	◆	◆
Dextromethorphan	◆	◆	◆	◆	◆	◆	◆	◆
Guaifenesin	◆	◆	◆	◆	◆	◆	◆	◆
Pseudoephedrine	◆	◆	◆	◆	◆	◆	◆	◆
Covid-19 Antiviral Therapies								
Casirivimab/Imdevimab	◆	◆	◆	◆	◆	◆	◆	◆
Ensitrelvir	◆	◆	◆	◆	◆	◆	◆	◆
Favipiravir	◆	◆	◆	◆	◆	◆	◆	◆
Molnupiravir	◆	◆	◆	◆	◆	◆	◆	◆
Niclosamide	◆	◆	◆	◆	◆	◆	◆	◆
Nirmatrelvir + ritonavir (5 day)	◆	◆	◆	◆	◆	◆	◆	◆
Nirmatrelvir + ritonavir (≥10 day)	◆	◆	◆	◆	◆	◆	◆	◆
Nitazoxanide	◆	◆	◆	◆	◆	◆	◆	◆
Remdesivir	◆	◆	◆	◆	◆	◆	◆	◆
Sotrovimab	◆	◆	◆	◆	◆	◆	◆	◆
Tixagevimab/Cilgavimab	◆	◆	◆	◆	◆	◆	◆	◆
Covid-19 Host-directed Therapies								
Anakinra	◆	◆	◆	◆	◆	◆	◆	◆
Baricitinib	◆	▲	◆	◆	◆	◆	◆	◆
Budesonide (inhaled)	▲	◆	◆	◆	◆	◆	◆	◆
Canakinumab	◆	◆	◆	◆	◆	◆	◆	◆
Covid 19 convalescent plasma	◆	◆	◆	◆	◆	◆	◆	◆
Covid-19 vaccines	◆	◆	◆	◆	◆	◆	◆	◆
Dexamethasone (low dose; ≤16 mg)	▲	◆	◆	◆	◆	◆	◆	◆
Fluvoxamine	◆	◆	◆	◆	◆	◆	◆	◆
Hydrocortisone (oral or IV)	▲	◆	◆	◆	◆	◆	◆	◆
Imatinib (14 days)	◆	◆	◆	◆	◆	◆	◆	▲
Infliximab	◆	◆	◆	◆	◆	◆	◆	◆
Methylprednisolone (oral or IV)	▲	◆	◆	◆	◆	◆	◆	◆
Ruxolitinib	◆	◆	◆	◆	◆	◆	◆	◆
Sarilumab	◆	◆	◆	◆	◆	◆	◆	◆
Tocilizumab	◆	◆	◆	◆	◆	◆	◆	◆
Vilobelimab	◆	◆	◆	◆	◆	◆	◆	◆
Cystic Fibrosis Agents								
Ivacaftor	●	◆	◆	◆	◆	◆	◆	◆
Ivacaftor/lumacaftor	●	◆	◆	◆	◆	◆	◆	▲
Ivacaftor/tezacaftor	●	◆	◆	◆	◆	◆	◆	◆
Ivacaftor/tezacaftor/elexacaftor	●	◆	◆	◆	◆	◆	◆	◆
Dementia Therapies								
Donepezil	▲	◆	◆	◆	▲	▲	◆	◆
Galantamine	◆	◆	◆	◆	◆	◆	◆	◆
Memantine	◆	◆	◆	◆	◆	◆	◆	◆
Rivastigmine	◆	◆	◆	◆	◆	◆	◆	◆
Erectile Dysfunction Agents								
Alprostadil	◆	◆	◆	◆	◆	◆	◆	◆
Avanafil	●	◆	◆	◆	●	●	◆	◆
Sildenafil (erectile dysfunction)	◆	◆	◆	◆	◆	◆	◆	◆
Tadalafil (erectile dysfunction)	◆	◆	◆	◆	◆	◆	◆	◆
Vardenafil	●	◆	◆	◆	●	●	◆	▲

	ESV	FAVI	MOL	NIC	NM/r 5 day	NM/r ≥10 day	NTZ	RDV
Gastrointestinal Agents								
Alosetron	◆	◆	◆	◆	◆	◆	◆	◆
Antacids	◆	◆	◆	◆	◆	◆	◆	◆
Bisacodyl	◆	◆	◆	◆	◆	◆	◆	◆
Bismuth subsalicylate	◆	◆	◆	◆	◆	◆	◆	◆
Cimetidine	◆	◆	◆	◆	◆	◆	◆	◆
Cisapride	●	◆	◆	◆	●	●	◆	◆
Dexlansoprazole	◆	◆	◆	◆	◆	◆	◆	◆
Dicycloverine	◆	◆	◆	◆	◆	◆	◆	◆
Docusate	◆	◆	◆	◆	◆	◆	◆	◆
Esomeprazole	◆	◆	◆	◆	◆	◆	◆	◆
Famotidine	◆	◆	◆	◆	◆	◆	◆	◆
Hyoscine butylbromide	◆	◆	◆	◆	◆	◆	◆	◆
Ispaghula husk	◆	◆	◆	◆	◆	◆	◆	◆
Lactulose	◆	◆	◆	◆	◆	◆	◆	◆
Lansoprazole	◆	◆	◆	◆	◆	◆	◆	◆
Linacotide	◆	◆	◆	◆	◆	◆	◆	◆
Loperamide	◆	◆	◆	◆	◆	◆	◆	◆
Macrogol (Polyethylene Glycol 3350)	▲	▲	▲	▲	▲	▲	▲	◆
Magnesium salts (oral)	◆	◆	◆	◆	◆	◆	◆	◆
Mebeverine	◆	◆	◆	◆	◆	◆	◆	◆
Mesalazine (mesalamine)	◆	◆	◆	◆	◆	◆	◆	◆
Naloxegol	●	◆	◆	◆	●	●	◆	◆
Nizatidine	◆	◆	◆	◆	◆	◆	◆	◆
Octreotide	◆	◆	◆	◆	◆	◆	◆	◆
Omeprazole	◆	◆	◆	◆	◆	◆	◆	◆
Pantoprazole	◆	◆	◆	◆	◆	◆	◆	◆
Psyllium husk	◆	◆	◆	◆	◆	◆	◆	◆
Prucalopride	◆	◆	◆	◆	◆	◆	◆	◆
Rabeprazole	◆	◆	◆	◆	◆	◆	◆	◆
Ranitidine	◆	◆	◆	◆	◆	◆	◆	◆
Senna	◆	◆	◆	◆	◆	◆	◆	◆
Sucralfate	◆	◆	◆	◆	◆	◆	◆	◆
Gastrointestinal Agents (anti-emetics)								
Aprepitant	◆	◆	◆	◆	◆	◆	◆	◆
Cyclizine	◆	◆	◆	◆	◆	◆	◆	◆
Dolasetron	◆	◆	◆	◆	◆	◆	◆	◆
Domperidone	●	◆	◆	◆	●	●	◆	◆
Dronabinol	◆	◆	◆	◆	◆	◆	◆	◆
Fosaprepitant	◆	◆	◆	◆	◆	◆	◆	◆
Granisetron	◆	◆	◆	◆	◆	◆	◆	▲
Hyoscine (Scopolamine)	◆	◆	◆	◆	◆	◆	◆	◆
Hyoscine hydrobromide	◆	◆	◆	◆	◆	◆	◆	◆
Metoclopramide	◆	◆	◆	◆	◆	◆	◆	◆
Netupitant	◆	◆	◆	◆	◆	◆	◆	◆
Ondansetron	◆	◆	◆	◆	◆	◆	◆	◆
Palonosetron	◆	◆	◆	◆	◆	◆	◆	▲
Prochlorperazine	◆	◆	◆	◆	◆	◆	◆	◆
Rolapitant	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ESV	Ensitrelvir	NIC	Niclosamide
FAVI	Favipiravir	NM/r	Nirmatrelvir/ritonavir
MOL	Molnupiravir	NTZ	Nitazoxanide
		RDV	Remdesivir

Key to symbols

●	These drugs should not be coadministered
◆	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?

Click or scan to check for updates



Interactions with COVID-19 Antiviral Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Please check www.covid19-druginteractions.org for updates.

Please note if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.
Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

	ESV	FAVI	MOL	NIC	NMVR/r 5 day	NMVR/r ≥10 day	NTZ	RDV
HCV DAAs								
Elbasvir/Grazoprevir	◆	◆	◆	◆	●	●	◆	◆
Glecaprevir/Pibrentasvir	◆	◆	◆	◆	●	●	◆	◆
Ledipasvir/Sofosbuvir	◆	◆	◆	◆	◆	◆	◆	◆
Ombitasvir/Paritaprevir/r	▲	◆	◆	◆	■	■	◆	◆
Ombitasvir/Paritaprevir/r + Dasabuvir	▲	◆	◆	◆	■	■	◆	◆
Sofosbuvir	◆	◆	◆	◆	◆	◆	◆	◆
Sofosbuvir/Velpatasvir	◆	◆	◆	◆	◆	◆	◆	◆
Sofosbuvir/Velpatasvir/Voxilaprevir	◆	◆	◆	◆	■	■	◆	◆
HIV Antiretroviral Therapies								
Abacavir	◆	◆	◆	◆	◆	◆	◆	◆
Albuvirtide	◆	◆	◆	◆	▲	▲	◆	◆
Atazanavir alone	▲	◆	◆	◆	■	■	◆	▲
Atazanavir + ritonavir	▲	■	◆	◆	■	■	◆	▲
Atazanavir/cobicistat	▲	◆	◆	◆	■	■	◆	▲
Bictegravir/Emtricitabine/TAF	◆	◆	◆	◆	◆	◆	◆	◆
Cabotegravir (oral)	◆	◆	◆	◆	◆	◆	◆	◆
Cabotegravir/rilpivirine (long acting)	◆	◆	◆	◆	◆	◆	◆	▲
Darunavir + ritonavir	▲	■	◆	◆	■	■	◆	◆
Darunavir/cobicistat	▲	◆	◆	◆	■	■	◆	◆
Darunavir/Cobi/Emtricitabine/TAF	▲	◆	◆	◆	■	■	◆	◆
Dolutegravir	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir/Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆
Dolutegravir/Rilpivirine	◆	◆	◆	◆	◆	◆	◆	▲
Dolutegravir/Abacavir/Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆
Doravirine	◆	◆	◆	◆	◆	◆	◆	◆
Doravirine/Lamivudine/Tenofovir-DF	◆	■	◆	◆	◆	◆	◆	◆
Efavirenz	■	■	◆	◆	▲	▲	◆	▲
Elvitegravir/Cobi/Emtricitabine/TAF	▲	◆	◆	◆	■	■	◆	◆
Elvitegravir/Cobi/Emtricitabine/TDF	▲	■	◆	◆	■	■	◆	◆
Emtricitabine	◆	◆	◆	◆	◆	◆	◆	◆
Emtricitabine/Tenofovir alafenamide	◆	◆	◆	◆	◆	◆	◆	◆
Emtricitabine/Tenofovir-DF	◆	■	◆	◆	◆	◆	◆	◆
Etravirine	■	■	◆	◆	◆	◆	◆	◆
Fostemsavir	◆	◆	◆	◆	◆	◆	◆	▲
Ibalizumab-uiyk	◆	◆	◆	◆	◆	◆	◆	◆
Lamivudine	◆	◆	◆	◆	◆	◆	◆	◆
Lenacapavir	▲	◆	◆	◆	▲	▲	◆	◆
Lopinavir/ritonavir	▲	■	◆	◆	■	■	◆	▲
Maraviroc	■	◆	◆	◆	■	■	◆	◆
Nevirapine	■	◆	◆	◆	▲	▲	◆	◆
Raltegravir	◆	◆	◆	◆	◆	◆	◆	◆
Rilpivirine	◆	◆	◆	◆	◆	◆	◆	▲
Rilpivirine/Emtricitabine/TAF	◆	◆	◆	◆	◆	◆	◆	▲
Rilpivirine/Emtricitabine/TDF	◆	■	◆	◆	◆	◆	◆	▲
Tenofovir-DF	◆	■	◆	◆	◆	◆	◆	◆
Zidovudine	◆	◆	◆	◆	◆	◆	◆	◆

	ESV	FAVI	MOL	NIC	NMVR/r 5 day	NMVR/r ≥10 day	NTZ	RDV
Hypertension / Heart Failure Agents								
Aliskiren	■	◆	◆	◆	●	●	◆	◆
Ambrisentan	◆	◆	◆	◆	◆	◆	◆	◆
Amiloride	◆	◆	◆	◆	◆	◆	◆	◆
Azilsartan	◆	◆	◆	◆	◆	▲	◆	◆
Benazepril	◆	◆	◆	◆	◆	◆	◆	◆
Bendroflumethiazide	◆	◆	◆	◆	◆	◆	◆	◆
Bosentan	■	◆	◆	◆	●	●	◆	◆
Bumetanide	◆	◆	◆	◆	◆	◆	◆	◆
Candesartan	◆	◆	◆	◆	◆	◆	◆	◆
Captopril	◆	◆	◆	◆	◆	◆	◆	◆
Chlortalidone (Chlorthalidone)	◆	◆	◆	◆	◆	◆	◆	◆
Cilazapril	◆	◆	◆	◆	◆	◆	◆	◆
Clonidine	◆	◆	◆	◆	◆	◆	◆	◆
Dopamine	◆	◆	◆	◆	◆	◆	◆	◆
Doxazosin	■	◆	◆	◆	■	■	◆	◆
Enalapril	◆	◆	◆	◆	◆	◆	◆	◆
Eplerenone	●	◆	◆	◆	●	●	◆	◆
Epoprostenol	◆	◆	◆	◆	◆	◆	◆	◆
Eprosartan	◆	◆	◆	◆	◆	◆	◆	◆
Finerenone	●	◆	◆	◆	●	●	◆	◆
Fosinopril	◆	◆	◆	◆	◆	◆	◆	◆
Furosemide	◆	◆	◆	◆	◆	◆	◆	◆
Glycerol trinitrate (Nitroglycerin)	◆	◆	◆	◆	◆	◆	◆	◆
Hydralazine	◆	◆	◆	◆	◆	◆	◆	◆
Hydrochlorothiazide	◆	◆	◆	◆	◆	◆	◆	◆
Iloprost	◆	◆	◆	◆	◆	◆	◆	◆
Indapamide	■	◆	◆	◆	■	■	◆	◆
Irbesartan	◆	◆	◆	◆	▲	▲	◆	◆
Isosorbide dinitrate	▲	◆	◆	◆	▲	▲	◆	◆
Ivabradine	●	◆	◆	◆	●	●	◆	■
Labetalol	◆	◆	◆	◆	■	■	◆	◆
Lacidipine	■	◆	◆	◆	■	■	◆	▲
Lercanidipine	●	◆	◆	◆	●	●	◆	◆
Lisinopril	◆	◆	◆	◆	◆	◆	◆	◆
Losartan	◆	◆	◆	◆	▲	▲	◆	◆
Macitentan	■	◆	◆	◆	■	■	◆	◆
Methyldopa	◆	◆	◆	◆	◆	◆	◆	◆
Metolazone	◆	◆	◆	◆	◆	◆	◆	◆
Midodrine	◆	◆	◆	◆	▲	▲	◆	◆
Minoxidil	◆	◆	◆	◆	◆	■	◆	◆
Moexipril	◆	◆	◆	◆	◆	◆	◆	◆
Moxonidine	◆	◆	◆	◆	◆	◆	◆	◆
Nicorandil	◆	◆	◆	◆	◆	◆	◆	◆
Olmesartan	◆	◆	◆	◆	◆	◆	◆	◆
Perindopril	◆	◆	◆	◆	◆	◆	◆	◆
Prazosin	◆	◆	◆	◆	◆	■	◆	◆
Quinapril	◆	◆	◆	◆	◆	◆	◆	◆
Ramipril	◆	◆	◆	◆	◆	◆	◆	◆
Ranolazine	●	◆	◆	◆	●	●	◆	◆
Riociguat	●	◆	◆	◆	■	■	◆	◆
Sacubitril	◆	◆	◆	◆	■	■	◆	◆
Selexipag	◆	◆	◆	◆	◆	◆	◆	◆
Sildenafil (PAH)	●	◆	◆	◆	●	●	◆	◆
Sodium nitroprusside	◆	◆	◆	◆	◆	◆	◆	◆
Spironolactone	◆	◆	◆	◆	◆	◆	◆	◆
Tadalafil (PAH)	●	◆	◆	◆	●	●	◆	◆
Telmisartan	◆	◆	◆	◆	◆	◆	◆	◆
Terazosin	■	◆	◆	◆	■	■	◆	◆
Torasemide	◆	◆	◆	◆	▲	▲	◆	◆
Trandolapril	◆	◆	◆	◆	◆	◆	◆	◆
Treprostinil	◆	■	◆	◆	▲	▲	◆	◆
Triamterene	◆	◆	◆	◆	▲	■	◆	◆
Valsartan	◆	◆	◆	◆	■	■	◆	◆
Xipamide	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations


ESV	Ensitrelvir	NIC	Niclosamide
FAVI	Favipiravir	NMVR/r	Nirmatrelvir/ritonavir
MOL	Molnupiravir	NTZ	Nitazoxanide
		RDV	Remdesivir

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with COVID-19 Antiviral Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Please check www.covid19-druginteractions.org for updates.

Please note if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers. Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

	ESV	FAVI	MOL	NIC	NMV/r 5 day	NMV/r ≥10 day	NTZ	RDV
Illicit/Recreational								
Alcohol	◆	◆	◆	◆	◆	◆	◆	◆
Amphetamine	◆	◆	◆	◆	■	■	◆	◆
Cannabis (Marijuana)	◆	◆	◆	◆	▲	▲	◆	◆
Carfentanil	●	◆	◆	◆	●	●	◆	◆
Cocaine	▲	◆	◆	◆	■	■	◆	■
Ecstasy (MDMA)	◆	◆	◆	◆	■	■	◆	◆
Enobosarm (Ostarine)	◆	◆	◆	◆	◆	▲	◆	◆
GHB (Gamma-hydroxybutyrate)	■	◆	◆	◆	■	■	◆	◆
Heroin	◆	◆	◆	◆	■	■	◆	◆
LSD (Lysergic acid diethylamide)	■	◆	◆	◆	■	■	◆	◆
Methamphetamine	◆	◆	◆	◆	■	■	◆	◆
Nitazenes	●	●	◆	◆	●	●	◆	◆
Poppers (Amyl nitrate)	◆	◆	◆	◆	◆	▲	◆	◆
Psilocybin	◆	◆	◆	◆	◆	▲	◆	◆
Trenbolone	◆	◆	◆	◆	◆	◆	◆	◆
Immunosuppressants								
Abatacept	◆	◆	◆	◆	◆	◆	◆	◆
Abrocitinib	◆	▲	◆	◆	◆	■	◆	◆
Adalimumab	◆	◆	◆	◆	◆	◆	◆	◆
Anti-thymocyte globulin	◆	◆	◆	◆	◆	◆	◆	◆
Apremilast	◆	◆	◆	◆	◆	◆	◆	◆
Azathioprine	◆	◆	◆	◆	◆	◆	◆	◆
Basiliximab	◆	◆	◆	◆	◆	◆	◆	◆
Belatacept	◆	◆	◆	◆	◆	◆	◆	◆
Belimumab	◆	◆	◆	◆	◆	◆	◆	◆
Bimekizumab	◆	◆	◆	◆	◆	◆	◆	◆
Certolizumab pegol	◆	◆	◆	◆	◆	◆	◆	◆
Ciclosporin	●	◆	◆	◆	■	■	◆	◆
Dimethyl fumarate	◆	◆	◆	◆	◆	◆	◆	◆
Etanercept	◆	◆	◆	◆	◆	◆	◆	◆
Everolimus	●	◆	◆	◆	■	●	◆	◆
Filgotinib	◆	◆	◆	◆	◆	◆	◆	◆
Golimumab	◆	◆	◆	◆	◆	◆	◆	◆
Ixekizumab	◆	◆	◆	◆	◆	◆	◆	◆
Leflunomide	◆	◆	◆	◆	◆	◆	◆	◆
Methotrexate	■	■	◆	◆	◆	◆	◆	◆
Mycophenolate	◆	◆	◆	◆	▲	■	◆	◆
Pirfenidone	◆	◆	◆	◆	▲	■	◆	◆
Risankizumab	◆	◆	◆	◆	◆	◆	◆	◆
Secukinumab	◆	◆	◆	◆	◆	◆	◆	◆
Sirrolimus	●	◆	◆	◆	■	●	◆	◆
Tacrolimus	●	◆	◆	◆	■	■	◆	▲
Tildrakizumab	◆	◆	◆	◆	◆	◆	◆	◆
Tofacitinib	■	◆	◆	◆	■	■	◆	◆
Upadacitinib	■	◆	◆	◆	■	■	◆	◆
Ustekinumab	◆	◆	◆	◆	◆	◆	◆	◆
Vedolizumab	◆	◆	◆	◆	◆	◆	◆	◆
Voclosporin	●	◆	◆	◆	●	●	◆	▲
Inotropes & Vasopressors								
Adrenaline (Epinephrine)	◆	◆	◆	◆	◆	◆	◆	◆
Desmopressin	◆	◆	◆	◆	◆	◆	◆	◆
Dobutamine	◆	◆	◆	◆	◆	◆	◆	◆
Noradrenaline	◆	◆	◆	◆	◆	◆	◆	◆
Vasopressin	◆	◆	◆	◆	◆	◆	◆	◆

	ESV	FAVI	MOL	NIC	NMV/r 5 day	NMV/r ≥10 day	NTZ	RDV
Lipid Lowering Agents								
Alirocumab	◆	◆	◆	◆	◆	◆	◆	◆
Atorvastatin	■	◆	◆	◆	■	■	◆	◆
Bempedoic acid	◆	◆	◆	◆	◆	▲	◆	◆
Bezafibrate	◆	◆	◆	◆	◆	◆	◆	◆
Clofibrate	◆	◆	◆	◆	◆	◆	◆	◆
Colesevelam	▲	▲	▲	◆	▲	▲	▲	◆
Colestyramine (Cholestyramine)	▲	▲	▲	◆	▲	▲	▲	◆
Evolocumab	◆	◆	◆	◆	◆	◆	◆	◆
Ezetimibe	◆	◆	◆	◆	◆	▲	◆	◆
Fenofibrate	◆	◆	◆	◆	◆	◆	◆	◆
Fish oils	◆	◆	◆	◆	◆	◆	◆	◆
Fluvastatin	◆	◆	◆	◆	◆	◆	◆	◆
Gemfibrozil	◆	◆	◆	◆	◆	▲	◆	◆
Icosapent ethyl	◆	◆	◆	◆	◆	◆	◆	◆
Inclisiran	◆	◆	◆	◆	◆	◆	◆	◆
Lomitapide	●	◆	◆	◆	●	●	◆	◆
Lovastatin	●	◆	◆	◆	●	●	◆	◆
Omega-3 fatty acids	◆	◆	◆	◆	◆	◆	◆	◆
Pitavastatin	◆	◆	◆	◆	◆	◆	◆	◆
Pravastatin	◆	◆	◆	◆	◆	◆	◆	◆
Rosuvastatin	■	◆	◆	◆	■	■	◆	◆
Simvastatin	●	◆	◆	◆	●	●	◆	◆
Multiple Sclerosis Agents								
Alemtuzumab	◆	◆	◆	◆	◆	◆	◆	◆
Baclofen	◆	◆	◆	◆	◆	◆	◆	◆
Cladribine	■	◆	◆	◆	■	■	◆	◆
Dantrolene sodium	◆	◆	◆	◆	◆	◆	◆	◆
Dimethyl fumarate	◆	◆	◆	◆	◆	◆	◆	◆
Fampridine	◆	◆	◆	◆	◆	◆	◆	◆
Fingolimod	◆	◆	◆	◆	◆	◆	◆	▲
Glatiramer acetate	◆	◆	◆	◆	◆	◆	◆	◆
Natalizumab	◆	◆	◆	◆	◆	◆	◆	◆
Ocrelizumab	◆	◆	◆	◆	◆	◆	◆	◆
Ozanimod	◆	■	◆	◆	◆	◆	◆	▲
Peginterferon beta-1a	◆	◆	◆	◆	◆	◆	◆	◆
Siponimod	◆	◆	◆	◆	▲	▲	◆	▲
Teriflunomide	◆	◆	◆	◆	◆	◆	◆	◆
Ophthalmological Agents								
Brimonidine	◆	◆	◆	◆	◆	◆	◆	◆
Brinzolamide	■	◆	◆	◆	■	■	◆	◆
Brolucizumab	◆	◆	◆	◆	◆	◆	◆	◆
Latanoprost	◆	◆	◆	◆	◆	◆	◆	◆
Ranibizumab	◆	◆	◆	◆	◆	◆	◆	◆
Travoprost	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ESV	Ensitrelvir	NIC	Niclosamide
FAVI	Favipiravir	NMV/r	Nirmatrelvir/ritonavir
MOL	Molnupiravir	NTZ	Nitazoxanide
		RDV	Remdesivir

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?

Click or scan to check for updates



Interactions with COVID-19 Antiviral Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 10 of 11

Please check www.covid19-druginteractions.org for updates.

Please note if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

	ESV	FAVI	MOL	NIC	NM/r 5 day	NM/r ≥10 day	NTZ	RDV
Other								
Acetazolamide	◆	◆	◆	◆	◆	◆	◆	◆
Acetylcysteine	◆	◆	◆	◆	◆	◆	◆	◆
Acitretin	◆	◆	◆	◆	◆	◆	◆	◆
Activated charcoal	▲	▲	▲	▲	▲	▲	▲	◆
Allopurinol	◆	▲	◆	◆	◆	◆	◆	◆
Atropine	◆	◆	◆	◆	◆	◆	◆	◆
Benralizumab	◆	◆	◆	◆	◆	◆	◆	◆
Betahistine	◆	◆	◆	◆	◆	◆	◆	◆
Bromocriptine	■	◆	◆	◆	■	■	◆	◆
Cannabidiol	■	◆	◆	◆	■	■	◆	◆
Carbimazole	◆	◆	◆	◆	◆	◆	◆	◆
Cinacalcet	■	◆	◆	◆	■	■	◆	▲
Clomifene	◆	◆	◆	◆	▲	▲	◆	◆
Colchicine	●	◆	◆	◆	●	●	◆	◆
Crizanlizumab	◆	◆	◆	◆	◆	◆	◆	◆
Cytisine (Cytisinicline)	◆	◆	◆	◆	◆	◆	◆	◆
Deferasirox	◆	◆	◆	◆	◆	■	◆	◆
Denosumab	◆	◆	◆	◆	◆	◆	◆	◆
Disulfiram	■	◆	◆	◆	■	◆	◆	◆
Drotaverine	◆	◆	◆	◆	◆	◆	◆	◆
Dupilumab	◆	◆	◆	◆	◆	◆	◆	◆
Elagolix	■	◆	◆	◆	■	■	◆	◆
Ergometrine (Ergonovine)	●	◆	◆	◆	●	●	◆	◆
Febuxostat	◆	◆	◆	◆	◆	◆	◆	◆
Fezolinetant	◆	◆	◆	◆	◆	◆	◆	◆
Filgrastim	◆	◆	◆	◆	◆	◆	◆	◆
Finasteride (1 mg)	◆	◆	◆	◆	◆	◆	◆	◆
Flibanserin	●	▲	◆	◆	●	●	◆	◆
Goserelin	◆	◆	◆	◆	◆	◆	◆	▲
Interferon beta	◆	◆	◆	◆	◆	◆	◆	◆
Isosorbide mononitrate	■	◆	◆	◆	▲	■	◆	◆
Ivermectin	■	◆	◆	◆	■	■	◆	◆
Leuprorelin	◆	◆	◆	◆	◆	◆	◆	▲
Levothyroxine	◆	◆	◆	◆	◆	■	◆	◆
Liothyronine	◆	◆	◆	◆	◆	◆	◆	◆
Magnesium sulphate (IV)	◆	◆	◆	◆	◆	◆	◆	◆
Melatonin	◆	◆	◆	◆	◆	▲	◆	◆
Mepolizumab	◆	◆	◆	◆	◆	◆	◆	◆
Methimazole	◆	◆	◆	◆	◆	◆	◆	◆
Methylergometrine	●	◆	◆	◆	●	●	◆	◆
Misoprostol	◆	◆	◆	◆	◆	◆	◆	◆
Modafinil	■	◆	◆	◆	◆	◆	◆	◆

	ESV	FAVI	MOL	NIC	NM/r 5 day	NM/r ≥10 day	NTZ	RDV
Other (continued)								
Naftidrofuryl	◆	◆	◆	◆	◆	◆	◆	◆
Naloxone	◆	◆	◆	◆	◆	◆	◆	◆
Naltrexone	◆	◆	◆	◆	◆	◆	◆	◆
Neostigmine	◆	◆	◆	◆	◆	◆	◆	◆
Nicotine	◆	◆	◆	◆	◆	◆	◆	◆
Nintedanib	■	◆	◆	◆	■	■	◆	◆
Omalizumab	◆	◆	◆	◆	◆	◆	◆	◆
Orlistat	▲	▲	▲	▲	▲	▲	▲	◆
Ospemifene	■	◆	◆	◆	■	■	◆	◆
Pancreatic enzymes (Creon)	◆	◆	◆	◆	◆	◆	◆	◆
Pentosan polysulfate sodium	◆	◆	◆	◆	◆	◆	◆	◆
Pentoxifylline	◆	◆	◆	◆	◆	◆	◆	◆
Phentermine	◆	◆	◆	◆	◆	◆	◆	◆
Phenylephrine	◆	◆	◆	◆	◆	◆	◆	◆
Pilocarpine	◆	◆	◆	◆	◆	◆	◆	◆
Pitolisant	◆	◆	◆	◆	◆	◆	◆	▲
Potassium	◆	◆	◆	◆	◆	◆	◆	◆
Probenecid	◆	◆	◆	◆	◆	◆	◆	◆
Propylthiouracil	◆	◆	◆	◆	◆	■	◆	◆
Pyridostigmine	◆	◆	◆	◆	◆	◆	◆	◆
Raloxifene	◆	◆	◆	◆	◆	◆	◆	◆
Ramelteon	■	◆	◆	◆	■	■	◆	◆
Riluzole	◆	◆	◆	◆	▲	■	◆	◆
Sevelamer	▲	▲	▲	▲	▲	▲	▲	◆
Sodium zirconium cyclosilicate	◆	◆	◆	◆	◆	◆	◆	◆
Sulfasalazine	■	◆	◆	◆	■	■	◆	◆
Tasimelteon	■	◆	◆	◆	■	■	◆	◆
Telotristat	■	◆	◆	◆	▲	▲	◆	◆
Tenapanor	◆	◆	◆	◆	◆	◆	◆	◆
Tolvaptan	●	◆	◆	◆	●	●	◆	◆
Triclabendazole	◆	◆	◆	◆	◆	◆	◆	▲
Triptorelin	◆	◆	◆	◆	◆	◆	◆	▲
Ursodeoxycholic acid (Ursodiol)	◆	◆	◆	◆	◆	◆	◆	◆
Varenicline	◆	◆	◆	◆	◆	◆	◆	◆
Overactive Bladder Agents								
Darifenacin	●	◆	◆	◆	●	●	◆	◆
Fesoterodine	■	◆	◆	◆	■	■	◆	◆
Mirabegron	■	◆	◆	◆	■	■	◆	▲
Oxybutynin	■	◆	◆	◆	■	■	◆	◆
Solifenacin	■	◆	◆	◆	■	■	◆	◆
Tolterodine	■	◆	◆	◆	■	■	◆	▲
Trospium	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ESV	Ensitrivir	NIC	Niclosamide
FAVI	Favipiravir	NM/r	Nirmatrelvir/ritonavir
MOL	Molnupiravir	NTZ	Nitazoxanide
		RDV	Remdesivir

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?

Click or scan to check for updates



Interactions with COVID-19 Antiviral Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Revised March 2025

Page 11 of 11

Please check www.covid19-druginteractions.org for updates.

Please note if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

	ESV	FAVI	MOL	NIC	NM/r 5 day	NM/r ≥10 day	NTZ	RDV
Parkinsonism Agents								
Amantadine	◆	◆	◆	◆	◆	◆	◆	◆
Apomorphine	◆	◆	◆	◆	◆	◆	◆	▲
Benserazide/levodopa	◆	◆	◆	◆	◆	◆	◆	◆
Benzatropine (Bentropine)	◆	◆	◆	◆	◆	◆	◆	◆
Biperiden	◆	◆	◆	◆	◆	◆	◆	◆
Cabergoline	◆	◆	◆	◆	■	■	◆	◆
Carbidopa	◆	◆	◆	◆	◆	◆	◆	◆
Carbidopa/levodopa	◆	◆	◆	◆	▲	▲	◆	◆
Entacapone	◆	◆	◆	◆	◆	■	◆	◆
Levodopa	◆	◆	◆	◆	◆	◆	◆	◆
Orphenadrine	▲	◆	◆	◆	▲	▲	◆	◆
Piribedil	▲	◆	◆	◆	▲	▲	◆	◆
Pramipexole	◆	◆	◆	◆	◆	◆	◆	◆
Procyclidine	▲	▲	◆	◆	▲	▲	◆	◆
Rasagiline	◆	◆	◆	◆	◆	■	◆	◆
Ropinirole	◆	◆	◆	◆	◆	■	◆	◆
Rotigotine	◆	◆	◆	◆	◆	◆	◆	◆
Safinamide	◆	◆	◆	◆	◆	◆	◆	◆
Selegiline	◆	◆	◆	◆	▲	■	◆	◆
Steroids								
Beclomethasone	◆	◆	◆	◆	◆	◆	◆	◆
Betamethasone	▲	◆	◆	◆	◆	▲	◆	◆
Betamethasone (topical)	◆	◆	◆	◆	◆	◆	◆	◆
Budesonide (oral/rectal)	▲	◆	◆	◆	◆	▲	◆	◆
Ciclesonide	▲	◆	◆	◆	◆	▲	◆	◆
Clobetasol	▲	◆	◆	◆	◆	▲	◆	◆
Deflazacort	■	◆	◆	◆	■	■	◆	◆
Dexamethasone (>16 mg)	■	■	◆	◆	■	■	◆	◆
Difluprednate	◆	◆	◆	◆	◆	◆	◆	◆
Fludrocortisone	▲	◆	◆	◆	◆	▲	◆	◆
Flunisolide	◆	◆	◆	◆	◆	◆	◆	◆
Fluocinolone	◆	◆	◆	◆	◆	▲	◆	◆
Fluticasone	▲	◆	◆	◆	◆	▲	◆	◆
Hydrocortisone (topical)	◆	◆	◆	◆	◆	◆	◆	◆
Megestrol acetate	◆	◆	◆	◆	◆	◆	◆	◆
Methylprednisolone (topical)	◆	◆	◆	◆	◆	◆	◆	◆
Mometasone	▲	◆	◆	◆	◆	▲	◆	◆
Nandrolone	◆	◆	◆	◆	◆	◆	◆	◆
Oxandrolone	◆	◆	◆	◆	◆	◆	◆	◆
Oxymetholone	◆	◆	◆	◆	◆	◆	◆	◆
Prednisolone	◆	◆	◆	◆	◆	◆	◆	◆
Prednisone	◆	◆	◆	◆	◆	◆	◆	◆
Stanozolol	◆	◆	◆	◆	◆	◆	◆	◆
Testosterone	◆	◆	◆	◆	◆	◆	◆	◆
Triamcinolone	■	◆	◆	◆	■	■	◆	◆

	ESV	FAVI	MOL	NIC	NM/r 5 day	NM/r ≥10 day	NTZ	RDV
Vitamins/Supplements/Herbals								
African potato	▲	◆	◆	◆	◆	◆	◆	◆
Ayahuasca	◆	◆	◆	◆	■	■	◆	◆
Beta-alanine	◆	◆	◆	◆	◆	◆	◆	◆
Branched chain amino acids	◆	◆	◆	◆	◆	◆	◆	◆
Caffeine (anhydrous powder)	◆	◆	◆	◆	◆	◆	◆	◆
Calcium supplements	◆	◆	◆	◆	◆	◆	◆	◆
Cat's claw (Uncaria tomentosa)	▲	◆	◆	◆	■	■	◆	◆
Coenzyme Q10 (Ubidecarenone)	◆	◆	◆	◆	◆	◆	◆	◆
Collagen hydrolysate	◆	◆	◆	◆	◆	◆	◆	◆
Creatine monohydrate	◆	◆	◆	◆	◆	◆	◆	◆
Cubeb pepper (Piper cubeba)	◆	◆	◆	◆	◆	◆	◆	◆
Ecdysterone	◆	◆	◆	◆	◆	◆	◆	◆
Echinacea	◆	◆	◆	◆	◆	◆	◆	◆
Enteric feeds	◆	◆	◆	◆	◆	◆	◆	◆
Ferrous fumarate	◆	◆	◆	◆	◆	◆	◆	◆
Ferrous sulfate	◆	◆	◆	◆	◆	◆	◆	◆
Folic acid	◆	◆	◆	◆	◆	◆	◆	◆
Garlic	■	◆	◆	◆	■	■	◆	◆
Ginger (Zingiber officinale)	◆	◆	◆	◆	◆	◆	◆	◆
Ginkgo biloba	■	◆	◆	◆	◆	◆	◆	◆
Ginseng (P ginseng, P quinquefolis)	◆	◆	◆	◆	◆	◆	◆	◆
Glucosamine	◆	◆	◆	◆	◆	◆	◆	◆
Grapefruit juice	◆	◆	◆	◆	◆	◆	◆	◆
Guggulsterone	■	◆	◆	◆	■	■	◆	◆
Homeopathic remedies	◆	◆	◆	◆	◆	◆	◆	◆
Hops (Humulus lupulus)	◆	◆	◆	◆	◆	◆	◆	◆
Iodine	◆	◆	◆	◆	◆	◆	◆	◆
Iron supplements	◆	◆	◆	◆	◆	◆	◆	◆
Liquorice (Glycyrrhiza glabra)	◆	◆	◆	◆	◆	◆	◆	◆
Malabar nut tree	■	◆	◆	◆	■	■	◆	◆
Milk thistle (Silymarin)	◆	◆	◆	◆	◆	◆	◆	◆
Multivitamins	◆	◆	◆	◆	◆	◆	◆	◆
Nicotinamide (Niacinamide)	◆	◆	◆	◆	◆	◆	◆	◆
Oral nutritional supplements	◆	◆	◆	◆	◆	◆	◆	◆
Quercetin	■	◆	◆	◆	■	■	◆	◆
Red yeast rice	●	◆	◆	◆	●	●	◆	◆
St John's wort	●	■	◆	◆	●	●	▲	◆
Turmeric (Curcumin)	◆	◆	◆	◆	◆	◆	◆	◆
Valerian	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin A (Retinol)	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B1 (Thiamine)	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B12 (Cyanocobalamin)	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B2 (Riboflavin)	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B3 (Niacin, nicotinic acid)	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B6 (Pyridoxine)	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin B7 (Biotin)	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin C (Ascorbic Acid)	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin D2 (Ergocalciferol)	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin D3 (Colecalciferol)	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin E (Tocopherol)	◆	◆	◆	◆	◆	◆	◆	◆
Vitamin K (Phytomenadione)	◆	◆	◆	◆	◆	◆	◆	◆
Whey protein	◆	◆	◆	◆	◆	◆	◆	◆
Zinc	◆	◆	◆	◆	◆	◆	◆	◆

Key to abbreviations

ESV	Ensitrelvir	NIC	Niclosamide
FAVI	Favipiravir	NM/r	Nirmatrelvir/ritonavir
MOL	Molnupiravir	NTZ	Nitazoxanide
		RDV	Remdesivir

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction which may require dose adjustment or close monitoring
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?

Click or scan to check for updates

